

## EDITORIAL COMMENT

# The Autonomic Nervous System and Cardiovascular Health and Disease



## A Complex Balancing Act\*

C. Noel Bairey Merz, MD, Omeed Elboudwarej, MD, Puja Mehta, MD

The cardiac autonomic nervous system (ANS) is a crucial component in physiological and pathological responses of the cardiovascular system. Through its 2 branches, the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS) nervous systems, as well as effector molecules including norepinephrine (NE) and acetylcholine, the ANS orchestrates many events that allow for appropriate blood pressure (BP), heart rate (HR), and vasoregulatory responses to routine daily stimuli. Dysregulation of this system due to aging,

acute and chronic stress, organic and idiopathic and other causes contributes to cardiovascular pathology, including hypertension, ischemic heart disease, arrhythmias, and congestive heart failure, and often contributes to fatal outcomes.

Heart failure with reduced ejection fraction (HFrEF) is characterized by neurohumoral activation mediated by the SNS and renin-angiotensin system (1). Sympathetic hyperactivity is evident by increased central sympathetic outflow and plasma NE levels, with NE spillover of up to 50-fold compared to that in controls (2,3). Even in HF patients with preserved EF (HFpEF), sympathetic hyperactivity represented by increased skeletal muscle nerve activity may contribute to the development of diastolic dysfunction (4). <sup>123</sup>I-labeled *metaiodobenzylguanidine* (MIBG) cardiac nuclear imaging assesses cardiac adrenergic nerve function and provides prognostic information for risk stratifying patients with HF (5).

Sympathetic hyperactivity in HF is related to a combination of suppression of the cardio-inhibitory reflexes, such as the baroreflex, and augmentation of the sympatho-excitatory reflexes, such as the afferent sympathetic reflex or the arterial chemoreceptor reflex (6). Within the central nervous system, both angiotensin II and aldosterone have been implicated in sympathetic activation through increased catecholamine release and decreased synaptic reuptake (7,8). This sympathetic hyperactivity affects excitation-contraction coupling and calcium signaling, thereby enhancing apoptosis and leading to progression of HF (9,10).

Other clinical conditions further implicate ANS balance playing a role in ventricular dysfunction. Stress cardiomyopathy, also known as Takotsubo cardiomyopathy or broken heart syndrome, although

---

\*Editorials published in *JACC: Heart Failure* reflect the views of the authors and do not necessarily represent the views of *JACC: Heart Failure* or the American College of Cardiology.

From the Barbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California. This work was supported by National Heart, Lung, and Blood Institutes contracts N01-HV-68161, N01-HV-68162, N01-HV-68163, N01-HV-68164, R01-HL-073412-01, K23 and HL105787; grants U0164829, U01 HL649141, and U01 HL649241; grants from the Gustavus and Louis Pfeiffer Research Foundation, the Women's Guild of Cedars-Sinai Medical Center, the Ladies Hospital Aid Society of Western Pennsylvania, and QMED, Inc.; and the Edythe L. Broad Endowment, the Barbra Streisand Women's Cardiovascular Research and Education Program, the Linda Joy Pollin Women's Heart Health Program, the Constance Austin Fellowship Endowment, the Cedars-Sinai Medical Center, and the Erika Glazer Women's Heart Health Project, Cedars-Sinai Medical Center. Dr. Bairey Merz has financial relationships with Gilead (grant review committee), Research Triangle Institute, Mayo Foundation (lecturer), Bryn Mawr Hospital (lecturer), Practice Point Communications (lecturer), Allegheny General Hospital (lecturer), Duke University (lecture), Japanese Circulation Society (lecturer), University of California-San Francisco (lecturer), Vox Media (lecturer), Emory University (lecturer), Preventive Cardiology Nurses Association (lecturer), Kaiser Permanente (lecturer), Garden State American Heart Association (lecturer), Victor Chang Cardiac Research Institute-Australia (lecturer), University of New Mexico (lecturer), and the National Institutes of Health Special Emphasis Panel (grant review study section). Dr. Mehta has received research support from Gilead. Dr. Elboudwarej has reported that he has no relationships relevant to the contents of this paper to disclose.

likely under-reported, appears to have the highest prevalence in post-menopausal women presenting with suspected acute coronary syndrome (11,12). Stress cardiomyopathy is characterized by an abnormal response to a catecholamine surge due to an emotional or a physical stressor, which leads to symptoms of chest pain and dyspnea, electrocardiographic changes, troponin elevation, and acute HF. In the most common variant of stress cardiomyopathy, apical ballooning with akinesis occurs with basal hyperkinesis, although other forms have been described (13). Apical ballooning is thought to be related to regional variation in the density of  $\beta$ -adrenergic receptors and increased sympathetic activity at the area of akinesis (14). A possible mechanism for high post-menopausal female prevalence may include the age-specific decrease in vagal tone and baroreceptor sensitivity from reduced estrogen levels, thereby augmenting the catecholamine-mediated stress response. Increased sympathetic activity and impaired baroreflex sensitivity has been shown in this stress cardiomyopathy (15). It remains unclear why most cases present in women, but recently, coronary endothelial and microvascular dysfunction have been implicated (16-18).

The prospective study of a 100 Dutch patients with HFrEF (left ventricular ejection fraction of <40%) who underwent mental stress testing adds to this understanding of the role the ANS balance plays in ventricular dysfunction. Kupper et al. (19) report that a reduced cardiovascular (diastolic BP) reactivity was associated with increased mortality on follow-up. The study further shows that increased mortality in chronic HF is associated with increased resting HR, reflecting resting sympathetic overdrive, suggesting that the increased mortality with lower blood pressure reactivity to mental stress is due to an exhausted sympathetic/cardiovascular response. These findings elaborate on the mechanism of benefit noted in prior

reports and clinical trials of beta blockade in heart patients (20).

In this issue of *JACC: Heart Failure*, Kupper et al. (19) further demonstrate the complex balancing act that ANS regulation plays in cardiovascular health and disease. Notably, a negative HR response (a drop in HR in response to mental stress) was associated with better survival, whereas a blunted diastolic BP response was associated with worsened survival (19). Although the authors discuss the fact that different mechanisms may underlie the blunted BP response compared to the reduction in HR (e.g., HR is relatively more regulated by autonomic control, whereas BP is more closely associated with endothelial dysfunction), previous mental stress testing work demonstrates a predictable, direct relationship between the R-R interval and BP response, such that a higher BP response is associated with slowing of the HR (21). The current study results suggest that this anticipated response, consistent with an intact cardiac ANS, in the setting of HF may be protective.

SEE PAGE 373

Taken together with previous reports, these new data are novel and hypothesis generating. We have proposed previously that PNS/SNS imbalance of the cardiac ANS is a potential mechanistic and therefore therapeutic target for ischemia (22), arrhythmias (23), and the metabolic syndrome (24), using mind-body and alternative and complementary interventions. Ongoing research in both HFrEF and HFpEF should further test ANS balance as a mechanistic pathway and therapeutic target, using both pharmacologic and mind-body techniques (25).

**REPRINT REQUESTS AND CORRESPONDENCE:** Dr. C. Noel Bailey Merz, Cedars-Sinai Heart Center, 127 S. San Vicente Boulevard, Suite A3600, Los Angeles, California 90048. E-mail: [merz@cshs.org](mailto:merz@cshs.org).

## REFERENCES

- Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. *Circulation* 1981;63:645-51.
- Pepper GS, Lee RW. Sympathetic activation in heart failure and its treatment with beta-blockade. *Arch Intern Med* 1999;159:225-34.
- Morris MJ, Cox HS, Lambert GW, et al. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. *Hypertension* 1997;29:137-43.
- Grassi G, Seravalle G, Quarti-Trevano F, et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. *Hypertension* 2009;53:205-9.
- Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. *J Am Coll Cardiol* 2010;55:2212-21.
- Watson AM, Hood SG, May CN. Mechanisms of sympathetic activation in heart failure. *Clin Exp Pharmacol Physiol* 2006;33:1269-74.
- Wang H, Huang BS, Ganten D, Leenen FH. Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen. *Circ Res* 2004; 94:843.
- Lal A, Veinot JP, Leenen FH. Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. *Cardiovasc Res* 2004;64:437-47.
- Piacentino V III, Weber CR, Chen X, et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. *Circ Res* 2003;92:651-8.
- Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. *N Engl J Med* 1997;336: 1131-41.

11. Strunk B, Shaw RE, Bull S, et al. High incidence of focal left ventricular wall motion abnormalities and normal coronary arteries in patients with myocardial infarctions presenting to a community hospital. *J Invasive Cardiol* 2006;18:376-81.
12. Pilgrim TM, Wyss TR. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: a systematic review. *Int J Cardiol* 2008;124:283-92.
13. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (Takotsubo) cardiomyopathy. *JAMA* 2011;306:277-86.
14. Prasad A, Madhavan M, Chareonthaitawee P. Cardiac sympathetic activity in stress-induced (Takotsubo) cardiomyopathy. *Nat Rev Cardiol* 2009;6:430-4.
15. Vaccaro A, Despas F, Delmas C, et al. Direct evidences for sympathetic hyperactivity and baroreflex impairment in Tako Tsubo cardiopathy. *PLoS One* 2014;9:e93278.
16. Bybee KA, Prasad A, Barsness GW, et al. Clinical characteristics and thrombolysis in myocardial infarction frame counts in women with transient left ventricular apical ballooning syndrome. *Am J Cardiol* 2004;94:343-6.
17. Kume T, Akasaka T, Kawamoto T, et al. Assessment of coronary microcirculation in patients with Takotsubo-like left ventricular dysfunction. *Circulation* 2005;69:934-9.
18. Patel SM, Lerman A, Lennon RJ, Prasad A. Impaired coronary microvascular reactivity in women with apical ballooning syndrome (Takotsubo/stress cardiomyopathy). *Eur Heart J* 2013;2:147-52.
19. Kupper N, Denollet J, Widdershoven J, Kop WJ. Cardiovascular reactivity to mental stress and mortality in patients with heart failure. *J Am Col Cardiol Heart Fail* 2015;3:373-82.
20. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur J Heart Fail* 2008;10:933-89.
21. Lipman RD, Grossman P, Bridges SE, Hamner JW, Taylor JA. Mental stress response, arterial stiffness, and baroreflex sensitivity in healthy aging. *J Gerontol A Biol Sci Med Sci* 2002;57:B279-84.
22. Mehta PK, Polk DM, Zhang X, et al. A randomized controlled trial of acupuncture in stable ischemic heart disease patients. *Int J Cardiol* 2014;176:367-74.
23. Bairey Merz CN, Dwyer J, Nordstrom CK, Walton KG, Salerno JW, Schneider RH. Psychosocial stress and cardiovascular disease: pathophysiological links. *Behav Med* 2002;27:141-7.
24. Paul-Labrador M, Polk D, Dwyer JH, et al. Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. *Arch Intern Med* 2006;166:1218-24.
25. Pepine CJ, Petersen JW, Bairey Merz CN. A microvascular-myocardial diastolic dysfunctional state and risk for mental stress ischemia: a revised concept of ischemia during daily life. *J Am Col Cardiol Img* 2014;7:362-5.

---

**KEY WORDS** autonomic nervous system, cardiovascular disease